Original Scientific Articles
Journal of Structural Heart Disease, September 2015, Volume 1, Issue 3:112-126
Update on New Devices for Transcatheter Aortic Valve Replacement
Heart Institute, Cedars-Sinai Medical Center, Los-Angeles, California, USA
Transcatheter aortic valve replacement (TAVR) for severe symptomatic aortic stenosis is the standard of care in inoperable patients and an alternative to surgical aortic valve replacement in high-risk operable patients. Several issues affecting outcomes with implantation of the first-generation TAVR devices remain unresolved, including neurological and vascular complications, atrioventicular conduction abnormalities, and paravalvular aortic regurgitation. New-generation TAVR devices are currently in different stages of clinical development and evaluation. Modifications in the new devices include the ability to reposition the valve before final deployment, features to reduce paravalvular leakage, lower-profile delivery systems, and cerebral protection devices. The purpose of this manuscript is to give an update on the new-generation transcatheter valvular technologies, focusing on the unique features and describing the initial clinical experience for each device.
Cite this article as: Abramowitz Y, Chakravarty T, Jilaihawi H, Makkar RR. Update on New Devices for Transcatheter Aortic Valve Replacement. Structural Heart Disease 2015;1(3):112-126. DOI: 10.12945/j.jshd.2015.019-14
You must be registered and logged in to leave comments.
There have been no comments posted yet
All comments will be screened and reviewed before posting. Statements, opinions, and results of studies published in Journal of Structural Heart Disease are those of the authors and do not reflect the policy or position of The Journal and Science International and the Editorial Board and provides no warranty as to their accuracy or reliability. Material is copyrighted and owned by Science International and cannot be used without expressed permission.